CVS Health Corporation (CVS) is a leading U.S. health solutions company with a market cap of $104.6 billion. CVS stock has surged 43.3% over the past 52 weeks, outperforming the S&P 500 Index. Despite reporting stronger-than-expected Q2 2025 earnings, CVS shares fell marginally due to a drop in GAAP earnings and net cash from operating activities. Analysts expect CVS’ adjusted EPS to grow by 17.3% this year. The consensus rating for CVS is a “Strong Buy,” with a mean price target of $86 and a Street-high target of $103. Morgan Stanley raised CVS Health’s price target to $89, indicating a potential 25.3% upside.

Read more at Barchart: Is Wall Street Bullish or Bearish on CVS Health Stock?